New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 20, 2014
07:56 EDTLCILannett digoxen use in clinics unlikely to change, says Canaccord
Canaccord said the use of Lannett's digoxen drug was only prescribed to critically ill Afib patients so the mortality risk cited in a retrospective study by Turakhia is not surprising. Given the risk of thrombotic events from Afib progression far outweighing the mortality risk the firm sees little change to clinical practice. Shares of Lannett are Buy rated with a $55 price target.
News For LCI From The Last 14 Days
Check below for free stories on LCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
11:01 EDTLCIActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
September 16, 2014
07:55 EDTLCILannett voluntarily conducts internal review in response to CT AG inquiry
Subscribe for More Information
September 10, 2014
13:36 EDTLCILannett receives FDA approval for oxycodone hydrochloride oral solution
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use